| Literature DB >> 12415690 |
Gautam Maulik1, Takashi Kijima, Ravi Salgia.
Abstract
Receptor tyrosine kinases are important in normal cellular physiology as well in the pathogenesis of a variety of tumors, including lung cancer. RTKs are a target for novel therapies currently being investigated. In the clinics, EGFR inhibitors and c-Kit inhibitors are already being utilized, and c-Met inhibitors are in development. Even though the RTK inhibitors provide a novel mechanism, it is important to realize that lung cancer etiology is a complex process, and eventually standard chemotherapy may need to be used in conjunction with these novel therapies to make an important difference in response rates.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12415690 DOI: 10.1385/1-59259-323-2:113
Source DB: PubMed Journal: Methods Mol Med ISSN: 1543-1894